Quand et comment traiter les hepatites B et C? [When and how to treat hepatitis B and C?]

Détails

ID Serval
serval:BIB_746FE98C8C45
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Quand et comment traiter les hepatites B et C? [When and how to treat hepatitis B and C?]
Périodique
Revue Médicale Suisse
Auteur(s)
Pache  I., Hess  J., Gonvers  J. J., Moradpour  D.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
01/2005
Volume
1
Numéro
3
Pages
237-41
Notes
English Abstract
Journal Article
Review --- Old month value: Jan 19
Résumé
The introduction of pegylated interferon-alpha (PEG-IFN-alpha) as well as lamivudine and adefovir has greatly improved the perspectives for patients with chronic hepatitis B. In addition, new nucleos(t)ide analogues are currently being evaluated and may allow the development of effective combination therapy regimens in the future. In the absence of resistance development, lamivudine reduces the risk of decompensation and hepatocellular carcinoma in patients with cirrhosis. Current standard therapy of chronic hepatitis C, PEG-IFN-alpha combined with ribavirin, results in a sustained virologic response in 20-80% of patients, depending on the viral genotype and additional factors, such as ethnicity, fibrosis stage, body mass index, viral load, alcohol consumption, and coinfections. Novel antiviral strategies are currently being explored.
Mots-clé
Antiviral Agents/*therapeutic use Carcinoma, Hepatocellular/pathology Drug Administration Schedule Drug Therapy, Combination Genotype Hepatitis B/complications/*drug therapy/pathology Hepatitis C/complications/*drug therapy/pathology Humans Liver Cirrhosis/prevention & control Liver Neoplasms/prevention & control
Pubmed
Création de la notice
25/01/2008 17:05
Dernière modification de la notice
03/03/2018 18:21
Données d'usage